Persistence of Immunogenicity Following Reduced PCV Dosing Schedules in South African Children (PCV1+1_FU)
Evaluation of Persistence of Immunogenicity Following an Open-labelled, Randomized Controlled Trial Evaluating Non-inferiority of 1+1 Compared to 2+1 Dosing Schedules of 10-valent and 13-valent Pneumococcal Conjugate Vaccine in South Africa
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Shabir A Madhi, MD PhD
- Phone Number: +27 11 983 4283
- Email: madhis@rmpru.co.za
Study Locations
-
-
Gauteng
-
Soweto, Gauteng, South Africa, 2013
- Chris Hani Baragwanath Academic Hospital - DST/NRF VPD RMPRU
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Children between and including the ages of 36 - 38 months of age at the time of first blood sampling;
- Subjects who previously participated in the PCV1+1 study and received the full study vaccination regime as per protocol;
- The parent or legal guardian of the child must be able and willing to provide written informed consent for all 3 visits and comply with all study requirements;
- The parent or legal guardian of the child must indicate the intention to remain in the study area for the duration of the trial - or be willing to bring the child for all visits.
Exclusion Criteria:
- Receipt of any additional pneumococcal vaccine since the end of participation in the PCV1+1 study;
- Any known or suspected immunodeficiency condition which could affect immune response to vaccination, including living with HIV;
- Receipt of any immunoglobulins and/or blood products less than 6 months prior to blood sampling;
- Parent/legal guardian unable or unwilling to attend scheduled study visits.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
PCV10 1+1, 6 weeks & 9 months
Follow-up of children who were previously randomized to PCV10 (Synflorix 0.5ml injection) administered at 6 weeks and 9 months of age.
|
0.5 ml injection
Other Names:
|
|
PCV13 1+1, 6 weeks & 9 months
Follow-up of children who were previously randomized to PCV13 (Prevnar 13, 0.5ml injection) administered at 6 weeks and 9 months of age.
|
0.5 ml injection
Other Names:
|
|
PCV10 1+1, 14 weeks & 9 months
Follow-up of children who were previously randomized to PCV10 (Synflorix 0.5ml injection) administered at 14 weeks and 9 months of age.
|
0.5 ml injection
Other Names:
|
|
PCV13 1+1, 14 weeks & 9 months
Follow-up of children who were previously randomized to PCV13 (Prevnar 13, 0.5ml injection) administered at 14 weeks and 9 months of age.
|
0.5 ml injection
Other Names:
|
|
PCV10 2+1, 6&14 weeks & 9 months
Follow-up of children who were previously randomized to PCV10 (Synflorix 0.5ml injection) administered at 6 weeks, 14 weeks and 9 months of age.
|
0.5 ml injection
Other Names:
|
|
PCV13 2+1, 6&14 weeks & 9 months
Follow-up of children who were previously randomized to PCV13 (Prevnar 13, 0.5ml injection) administered at 6 weeks, 14 weeks and 9 months of age.
|
0.5 ml injection
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Serotype specific geometric mean antibody concentrations (GMC)
Time Frame: 3, 4 and 5 years of age
|
To evaluate persistence of vaccine-serotype specific GMCs at 3, 4 and 5 years of age between children receiving differing 1+1 dosing schedules compared to the 2+1 dosing schedule of the same vaccine formulation (i.e.
PCV10 or PCV13).
|
3, 4 and 5 years of age
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Modified threshold of protection
Time Frame: 3, 4 and 5 years of age
|
To evaluate persistence of vaccine-serotype specific serum IgG antibody concentration above the WHO-defined putative threshold for protection (≥0.35 µg/mL) and the modified serotype-specific correlate of protection against IPD as proposed by Andrews et al.(17) at 3, 4 and 5 years of between children with differing 1+1 dosing schedules compared to the 2+1 dosing schedule of the same vaccine formulation
|
3, 4 and 5 years of age
|
|
Comparison between 6-week and 14-week primary dose
Time Frame: 3, 4 and 5 years of age
|
To evaluate persistence of vaccine-serotype specific serum IgG antibody concentration above the WHO-defined putative threshold for protection (≥0.35 µg/mL), the modified serotype-specific correlate of protection against IPD as proposed by Andrews et al. (17) and GMC's at 3, 4 and 5 years in children receiving the 1+1 dosing schedule at either 6 weeks of age compared to those who received it at 14 weeks of age, stratified for the individual vaccine formulation (PCV10 and PCV13).
|
3, 4 and 5 years of age
|
|
Colonization outcome
Time Frame: 3, 4 and 5 years of age
|
To compare the prevalence of vaccine-serotype (stratified by PCV10 and PCV13 serotypes)
|
3, 4 and 5 years of age
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Colonization outcome
Time Frame: 3, 4 and 5 years of age
|
To compare the prevalence of vaccine-serotype (stratified by PCV10 and PCV13 serotypes) and non-vaccine serotype nasopharyngeal colonization at 3, 4 and 5 years of age for the 1+1 dosing schedule groups compared to the 2+1 groups.
|
3, 4 and 5 years of age
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Shabir A Madhi, MD PhD, University of the Witwatersrand, South Africa
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- PCV1+1 follow-up
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.